8-K: Ingersoll Rand Reports Record Q2 Orders and Revenue, Raises Full-Year Guidance Despite Non-Cash Impairments

Ingersoll Rand Inc. announced record second quarter 2025 orders, revenues, and adjusted EBITDA, while raising its full-year guidance for revenue, adjusted EBITDA, and adjusted EPS, despite reporting a net loss primarily due to non-cash impairments.

Summary

• Reported orders reached a record $1,940 million, an 8% increase compared to the second quarter of 2024.
• Reported revenues hit a record $1,888 million, up 5% year-over-year.
• Adjusted EBITDA was a record $509 million, up 3%, with a margin of 27.0%.
• The company reported a net loss attributable to Ingersoll Rand Inc. of $115 million, or $0.29 per share, primarily due to $265.8 million in non-cash impairments.
• Adjusted net income was $325 million, or $0.80 per share.
• Operating cash flow was $246 million and free cash flow was $210 million for the quarter.
• Liquidity stood at $3.9 billion as of June 30, 2025, including $1.3 billion of cash on hand.
• Net debt to Adjusted EBITDA leverage decreased by 0.3x year-over-year to 1.7x.
• Ingersoll Rand deployed $47 million to M&A and returned $508 million to shareholders through $500 million in share repurchases and $8 million in quarterly dividends.
• Full-year 2025 guidance was raised for total revenue (4-6% growth), Adjusted EBITDA ($2,100M $2,160M, +4% +7% YoY), and Adjusted EPS ($3.34 $3.46, +2% +5% YoY).

Sentiment

Score: 8

Explanation: Despite a reported net loss due to non-cash impairments, the underlying operational performance is strong with record orders, revenue, and Adjusted EBITDA. The company also raised its full-year guidance for key financial metrics and is actively returning capital to shareholders through buybacks and dividends. The impairments are specific and non-recurring in nature, not indicative of core business weakness.

Positives

• Achieved record second quarter orders of $1,940 million, an 8% increase year-over-year.
• Delivered record second quarter revenues of $1,888 million, up 5% from the prior year.
• Reported record Adjusted EBITDA of $509 million, a 3% increase year-over-year.
• Raised full-year 2025 guidance for total revenue, Adjusted EBITDA, and Adjusted EPS, indicating strong future expectations.
• Maintained strong liquidity of $3.9 billion, including $1.3 billion in cash.
• Reduced net debt to Adjusted EBITDA leverage to 1.7x, a 0.3x decrease from the prior year.
• Demonstrated commitment to shareholder returns by deploying $500 million in share repurchases and $8 million in dividends.
• Successfully closed two strategic acquisitions, Lead Fluid and Termomeccanica Industrial Compressor S.p.A. (TMIC), expanding market reach and capabilities.
• Industrial Technologies and Services (IT&S) segment saw its second consecutive quarter of organic orders growth with a book-to-bill ratio of 1.05x.
• Precision and Science Technologies (P&ST) segment's Adjusted EBITDA margin continued to improve sequentially, up 40 basis points from Q1 and 190 basis points from Q4 2024.

Negatives

• Reported a net loss attributable to Ingersoll Rand Inc. of $115 million, or $0.29 per share, compared to net income of $185 million in the prior year quarter.
• The net loss was primarily driven by $265.8 million in non-cash impairments related to a minority stake in the High Pressure Solution business, ILC Dover Aerospace & Defense, and ILC Dover Biopharma.
• Adjusted net income decreased to $325 million from $341 million in the prior year quarter.
• Adjusted diluted EPS decreased to $0.80 from $0.83 in the prior year quarter.
• Operating cash flow decreased to $246 million from $305 million in the prior year quarter.
• Free cash flow decreased to $210 million from $283 million in the prior year quarter.
• Industrial Technologies and Services (IT&S) segment experienced a 4% organic revenue decline and a 2% decrease in Adjusted EBITDA.
• Precision and Science Technologies (P&ST) segment saw a 2% organic revenue decline and a 5% organic orders decline, primarily due to non-recurring large orders in the prior year.

Risks

• Adverse impact on operations and financial performance due to natural disaster, catastrophe, global pandemics, geopolitical tensions, cyber events, or other events outside of control.
• Unexpected costs, charges or expenses resulting from completed and proposed business combinations.
• Uncertainty of the expected financial performance of the Company.
• Failure to realize the anticipated benefits of completed and proposed business combinations.
• Difficulties and delays in achieving revenue and cost synergies.
• Inability to retain and hire key personnel.
• Evolving legal, regulatory and tax regimes.
• Changes in general economic and/or industry specific conditions.
• Actions by third parties, including government agencies.

Future Outlook

Ingersoll Rand is raising its full-year 2025 guidance for total revenue to 4-6% growth, Adjusted EBITDA to a range of $2,100 million to $2,160 million (4-7% year-over-year growth), and Adjusted EPS to a range of $3.34 to $3.46 (2-5% year-over-year growth). The company anticipates approximately 1% positive impact from foreign exchange and around $375 million from M&A on revenue.

Management Comments

• "We delivered another strong quarter, with momentum reflected in our first half organic orders growth, robust book-to-bill ratio, and raised guidance on revenue, Adjusted EBITDA, and Adjusted EPS."
• "Our M&A pipeline remains active and we are now more than halfway toward our annualized inorganic growth target."
• "We remain confident that our Economic Growth Engine and IRX combined with our ownership mindset will continue to drive long-term value creation."

Industry Context

Ingersoll Rand operates in the mission-critical flow creation and life science and industrial solutions sectors. The company's performance, marked by record orders and revenue, suggests resilience and growth in its core markets, despite some organic revenue declines in specific segments. The strategic acquisitions in fluid handling for life science and engineered-to-order solutions for renewable natural gas indicate a focus on high-growth, specialized areas within the broader industrial and life sciences industries, aligning with trends towards sustainability and advanced manufacturing.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders benefit from the company's strong operational performance, record orders and revenue, and increased full-year guidance, which could lead to future share price appreciation.
• Shareholders also directly benefit from the $500 million in share repurchases and $8 million in quarterly dividend payments, enhancing shareholder value and returns.
• Creditors are positively impacted by the company's strong liquidity position of $3.9 billion and a reduced net debt to Adjusted EBITDA leverage of 1.7x, indicating robust financial health and ability to service debt.
• Customers are likely to benefit from the company's continued investment in strategic acquisitions (Lead Fluid, TMIC) and commercial investments, which enhance product offerings and service capabilities in mission-critical and life science applications.

Next Steps

• Host a live earnings conference call on Friday, August 1, 2025, to discuss the second quarter results.

Key Dates

Recommendation

Despite a reported net loss, it is crucial for a seasoned investor to recognize that this loss is primarily due to significant non-cash impairments, which do not reflect the core operational health or cash-generating capabilities of the business. The company delivered record orders, revenue, and Adjusted EBITDA, demonstrating strong underlying business momentum. Furthermore, management raised its full-year guidance for revenue, Adjusted EBITDA, and Adjusted EPS, signaling confidence in continued growth and profitability. The active M&A strategy and substantial capital return to shareholders through buybacks and dividends further underscore a robust financial position and a commitment to enhancing shareholder value. These factors collectively suggest a positive outlook for the stock, making it an attractive 'buy' for investors focusing on long-term operational strength and strategic growth.

Keywords

Industrial Solutions, Life Sciences, Flow Creation, Compressors, Pumps, Fluid Handling, Industrial Technologies, Financial Results, Earnings, Guidance, M&A, Share Repurchase, Adjusted EBITDA, Free Cash Flow, Impairment